Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

References

Page 1

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Robert A. Burger, Mark F. Brady, Michael A. Bookman, New England Journal of Medicine	2011	2.3K
A Phase 3 Trial of Bevacizumab in Ovarian Cancer Timothy Perren, Ann Marie Swart, Jacobus Pfisterer, New England Journal of Medicine	2011	2.1K
Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study Roberta De Angelis, Milena Sant, Michel P. Coleman, The Lancet Oncology Cancer EpidemiologyMedicineGlobal HealthCancer SurvivalEurope 1999–2007	2013	1.9K
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial Éric Pujade-Lauraine, Felix Hilpert, B. Weber, Journal of Clinical Oncology	2014	1.6K
Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects Patrick Royston, Mahesh Parmar Statistics in Medicine Cox ModelsPrognosisEpidemiology Of CancerTreatment EffectProportional‐odds Models	2002	1.4K
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff, Journal of Clinical Oncology	2012	1.4K
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Jaafar Bennouna, Javier Sastre, Dirk Arnold, The Lancet Oncology Gastrointestinal OncologyMedicineRandomised Phase 3Colorectal CancerPathology	2012	1.2K
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi, The Lancet Advanced Ovarian CancerMedicineMetronomic TherapyPharmacologyDose-dense Paclitaxel	2009	731
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Robert A. Burger, Mark F. Brady, Michael A. Bookman, Obstetrical & Gynecological Survey Progression-free SurvivalControl GroupOncologyRecurrent Ovarian TumorsMedicine	2012	240

Page 1